The allergen-specificity of allergen immunotherapy - doubt no more.

Authors:
Stephen R Durham
Stephen R Durham
National Heart and Lung Institute
United Kingdom

Allergy 2019 Apr 20. Epub 2019 Apr 20.

National Heart and Lung Institute, Imperial College London, Dovehouse Street, London.

The ARIA-GA2LEN collaboration published a guide for the design and evaluation of randomised controlled trials of allergen immunotherapy for allergic rhinitis. Several problems in were identified. For example, the severity/persistence of seasonal symptoms in subjects during allergen immunotherapy was noted to be much lower than in trials of pharmacotherapy. The drop-out rates were higher. Seasonal pollen counts varied markedly between study centres and year-on-year during long-term trials thereby confounding the ability to detect treatment effects during 'low' pollen seasons. Placebo unmasking occurred due to the local side effects of allergen immunotherapy in actively treated participants. This article is protected by copyright. All rights reserved.

Download full-text PDF

Source
http://dx.doi.org/10.1111/all.13826DOI Listing
April 2019
1 Read

Publication Analysis

Top Keywords

allergen immunotherapy
16
study centres
4
centres year-on-year
4
markedly study
4
varied markedly
4
year-on-year long-term
4
long-term trials
4
ability detect
4
confounding ability
4
trials confounding
4
counts varied
4
pollen counts
4
lower trials
4
immunotherapy lower
4
subjects allergen
4
trials pharmacotherapy
4
pharmacotherapy drop-out
4
higher seasonal
4
rates higher
4
drop-out rates
4

Similar Publications